| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S19457 R82946 |
Straub (Controls exposed to LTG) (Carbamazepine) (Epilepsy), 2026 | Attention deficit hyperactivity disorder (ADHD) - ICD-10 codes: F90.x - Mean follow up (full cohort): 3.4 years | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
2.31 [1.75;3.05] C excluded (control group) |
107/1,548 102/3,273 | 209 | 1,548 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S19467 R83023 |
Straub (Controls unexposed, sick) (Carbamazepine) (Epilepsy), 2026 | Attention deficit hyperactivity disorder (ADHD) - ICD-10 codes: F90.x - Mean follow up (full cohort): 3.4 years | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes | 1.13 [0.89;1.43] | 107/1,548 366/8,887 | 473 | 1,548 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17426 R73195 |
Madley-Dowd_SE (Carbamazepine) (Controls exposed to LTG), 2024 | Attention Deficit Hyperactivity Disorder - ICD-8/9/10 codes and/or ADHD medication prescription - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No Partial overlapping |
2.40 [1.88;3.06] C excluded (control group) |
190/1,842 109/2,383 | 299 | 1,842 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17427 R73196 |
Madley-Dowd_SE (Carbamazepine) (Controls unexposed, sick), 2024 | Attention Deficit Hyperactivity Disorder - ICD-8/9/10 codes and/or ADHD medication prescription - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes Partial overlapping | 1.00 [0.85;1.18] | 190/1,842 929/10,769 | 1,119 | 1,842 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17257 R72271 |
Madley-Dowd_UK (Carbamazepine) (Controls exposed to LTG), 2024 | Attention Deficit Hyperactivity Disorder - ICD10 codes and/or ADHD medication prescription - Median CBZ 9.17 (5.31-12.54) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
1.36 [0.61;3.02] C excluded (control group) |
11/460 14/791 | 25 | 460 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17107 R72272 |
Madley-Dowd_UK (Carbamazepine) (Controls unexposed, sick), 2024 | Attention Deficit Hyperactivity Disorder - ICD10 codes and/or ADHD medication prescription - Median CBZ 9.17 (5.31-12.54) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes | 2.29 [1.14;4.60] | 11/460 38/4,075 | 49 | 460 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15868 R65361 |
Dreier (Carbamazepine) (Epilepsy) (Controls exposed to LTG), 2023 | Attention-deficit/hyperactivity disorder (ADHD) - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
1.89 [1.41;2.53] C excluded (control group) |
89/2,665 95/5,288 | 184 | 2,665 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15869 R65377 |
Dreier (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023 | Attention-deficit/hyperactivity disorder (ADHD) - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: Yes | 1.05 [0.81;1.37] | 89/2,665 528/22,203 | 617 | 2,665 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7510 R46610 |
Huber-Mollema (Carbamazepine), 2019 | Diagnosis of ADHD | throughout pregnancy | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.95 [0.18;5.12] C | 2/37 5/88 | 7 | 37 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6661 R46606 |
Bromley (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013 | Attention deficit hyperactivity disorder (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.82 [0.07;46.28] C excluded (control group) |
1/50 0/30 | 1 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6660 R46607 |
Bromley (Carbamazepine) (Controls unexposed, disease free), 2013 | Attention deficit hyperactivity disorder (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
13.21 [0.53;329.15] C excluded (control group) |
1/50 0/214 | 1 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5486 R46608 |
Bromley (Carbamazepine) (Controls unexposed, sick), 2013 | Attention deficit hyperactivity disorder (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 1.58 [0.06;40.13] C | 1/50 0/26 | 1 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5542 R46609 |
Cohen (Carbamazepine), 2013 | Children with either ADHD inattentive OR combined types > 1 SD (from the Attention Problems and Hyperactivity scales of the BASC) (Both Parent and Teacher) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.96 [0.22;4.25] C | 4/32 4/31 | 8 | 32 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6356 R46612 |
Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) b, 2013 | ADHD symptoms ≥ 2SD (at 36 months) (Specific checklist) (Parent-reported) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.94 [0.15;6.00] C excluded (control group) |
2/31 3/44 | 5 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6354 R46613 |
Veiby (Carbamazepine) (Controls unexposed, disease free) b, 2013 | ADHD symptoms ≥ 2SD (at 36 months) (Specific checklist) (Parent-reported) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
2.00 [0.50;8.60] excluded (control group) |
2/31 1,743/43,571 | 1,745 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6355 R46614 |
Veiby (Carbamazepine) (Controls unexposed, sick) b, 2013 | ADHD symptoms ≥ 2SD (at 36 months) (Specific checklist) (Parent-reported) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 2.59 [0.45;14.78] C | 2/31 4/154 | 6 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5831 R46615 |
Viinikainen (Carbamazepine) b, 2006 | Conners' Teacher Rating Scale Global Index scores >1 SD | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 0.15 [0.01;3.50] C | 0/12 2/11 | 2 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 9 studies | 1.07 [0.95;1.20] | 2,282 | 6,677 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick) (Carbamazepine) (Epilepsy; 2: Carbamazepine) (Controls unexposed, sick; 3: Carbamazepine) (Controls unexposed, sick; 4: Carbamazepine) (Epilepsy) (Controls unexposed, sick; 5: Carbamazepine; 6: Carbamazepine) (Controls unexposed, sick; 7: Carbamazepine; 8: Carbamazepine) (Controls unexposed, sick) ; 9: Carbamazepine) ;
Asymetry test p-value = 0.5288 (by Egger's regression)
slope=0.0239 (0.0874); intercept=0.3230 (0.4875); t=0.6626; p=0.5288
excluded 6661, 6660, 6356, 6354, 15868, 17426, 17257, 19457